This study uncovers a previously unrecognized mechanism by which palmitoylation regulates ferroptosis through modulating ACSL4 stability, and highlights the ZDHHC2‐USP19‐ACSL4 axis as a druggable target for overcoming resistance in advanced prostate cancer. This evidence concerns the gene ACSL4 and prostate carcinoma.